Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers

Human Brain Mapping

Volumn 30, Issue 2, 2009, Pages 511-522

  Eser, Daniela ^a   Leicht, Gregor ^a   Lutz, Jürgen ^b   Wenninger, Stephan ^a   Kirsch, Valerie ^a   Schüle, Cornelius ^a   Karch, Susanne ^a   Baghai, Thomas ^a   Pogarell, Oliver ^a   Born, Christine ^b   Rupprecht, Rainer ^a   Mulert, Christoph ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

ACC; Amygdala; Anxiety; CCK 4; FMRI

Indexed keywords

PLACEBO; TETRAGASTRIN;

ADULT; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; BRAIN MAPPING; BRAIN REGION; BRAIN STEM; CEREBELLUM; CINGULATE GYRUS; CONTROLLED STUDY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMAN EXPERIMENT; MALE; NEUROANATOMY; NORMAL HUMAN; OCCIPITAL LOBE; PANIC; PRIORITY JOURNAL;

ADULT; AMYGDALA; ANXIETY; BRAIN; BRAIN MAPPING; FEAR; GYRUS CINGULI; HUMANS; LIMBIC SYSTEM; MAGNETIC RESONANCE IMAGING; MALE; NERVE NET; PANIC DISORDER; TETRAGASTRIN; YOUNG ADULT;

EID: 59949094249     PISSN: 10659471     EISSN: None     Source Type: Journal    
DOI: 10.1002/hbm.20522     Document Type: Article

References (60)

1. Akiyoshi J, Isogawa K, Tsutsumi T, Kasturagi S, Kohno K, Furuta M, Yamamoto Y, Yamada K, Fujii I (1997): Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia. Biol Psychiatry 42:151-154.
2. Aluoja A, Shlik J, Vasar V, Kingisepp PH, Jagomagi K, Vasar E, Bradwejn J (1997): Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Psychiatry Res 66:59-67.
3. Aronson TA, Whitaker-Azmitia P, Caraseti I (1989): Differential reactivity to lactate infusions: the relative role of biological, psychological, and conditioning variables. Biol Psychiatry 25:469-481.
4. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ (1981): The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 212:51-57.
5. Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A, Evans A (1995): Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry 152:1180-1184.
6. Birbaumer N, Grodd W, Diedrich O, Klose U, Erb M, Lotze M, Schneider F, Weiss U, Flor H (1998): fMRI reveals amygdala activation to human faces in social phobics. Neuroreport 9:1223-1226.
7. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA (2002): rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52:126-135.
8. Bradwejn J, Koszycki D (1994a): Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151:261-263.
9. Bradwejn J, Koszycki D (1994b): The cholecystokinin hypothesis of anxiety and panic disorder. Ann NY Acad Sci 713:273-282.
10. Bradwejn J, Koszycki D (2001): Cholecystokinin and panic disorder: Past and future clinical research strategies. Scand J Clin. Lab Invest 61(Suppl):19-27.
11. Bradwejn J, Koszycki D, Meterissian G (1990): Cholecystokinin- tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85.
12. Bradwejn J, Koszycki D, Shriqui C (1991): Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48:603-610.
13. Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H (1992): Replication of action of cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings. Am J Psychiatry 149:962-964.
14. Bradwejn J, Koszycki D, Couetoux du TA, van Megen H, den Boer J, Westenberg H (1994): The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51:486-493.
15. Bradwejn J, LeGrand JM, Koszycki D, Bates JH, Bourin M (1998): Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry 155:280-282.
16. Brambilla F, Bellodi L, Perna G, Garberi A, Panerai A, Sacerdote P (1993): Lymphocyte cholecystokinin concentrations in panic disorder. Am J Psychiatry 150:1111-1113.
17. Breiter HC, Etcoff NL, Whalen PJ, Kennedy WA, Rauch SL, Buckner RL, Strauss MM, Hyman SE, Rosen BR (1996): Response and habituation of the human amygdala during visual processing of facial expression. Neuron 17:875-887.
18. Buchel C, Morris J, Dolan RJ, Friston KJ (1998): Brain systems mediating aversive conditioning: An event-related fMRI study. Neuron 20:947-957.
19. Bush G, Luu P, Posner MI (2000): Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci 4:215-222.
20. Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LL, Parvizi J, Hichwa RD (2000): Subcortical and cortical brain activity during the feeling of self-generated emotions. Nat Neurosci 3:1049-1056.
21. Davidson RJ, Irwin W (1999): The functional neuroanatomy of emotion and affective style. Trends Cogn Sci 3:11-21.
22. de Montigny C (1989): Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 46:511-517.
23. Devinsky O, Morrell MJ, Vogt BA (1995): Contributions of anterior cingulate cortex to behaviour. Brain 118:279-306.
24. Eser D, Schüle C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, de la MS, Engel R, Kucher K, Rupprecht R (2007): Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology 192:479-487.
25. Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J (1998): Effect of aging on cholecystokinin-induced panic. Am J Psychiatry 155:283-285.
26. Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000): Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157:493-505.
27. Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, Klein S, Grusser SM, Flor H, Schumann G, Mann K, Buchel C (2005): Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 8:20-21.
28. Javanmard M, Shlik J, Kennedy SH, Vaccarino FJ, Houle S, Bradwejn J (1999): Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: A comparison of two time points. Biol Psychiatry 45:872-882.
29. Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O (1999): Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4:284-285.
30. Koszycki D, Cox BJ, Bradwejn J (1993): Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry 150:1881-1883.
31. Koszycki D, Zacharko RM, Bradwejn J (1996a): Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. Psychiatry Res 62:131-138.
32. Koszycki D, Zacharko RM, Le Melledo JM, Young SN, Bradwejn J (1996b): Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry 40:648-655.
33. Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J (1998): Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: A comparison of panickers and nonpanickers. Depress Anxiety 8:1-7.
34. LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA (1998): Human amygdala activation during conditioned fear acquisition and extinction: A mixed-trial fMRI study. Neuron 20:937-945.
35. Le Melledo JM, Bradwejn J, Koszycki D, Bichet D (1995): Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry 52:605-606.
36. Le Melledo JM, Merani S, Koszycki D, Bellavance F, Palmour R, Gutkowska J, Steinberg S, Bichet DG, Bradwejn J (1999): Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD): During their follicular and luteal phases. Neuropsychopharmacology 20:81-91.
37. Le Melledo JM, Arthur H, Dalton J, Woo C, Lipton N, Bellavance F, Koszycki D, Boulenger JP, Bradwejn J (2001): The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. J Psychosom Res 51:513-520.
38. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC (1992): CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 149:691-693.
39. Moran TH, Robinson PH, Goldrich MS, McHugh PR (1986): Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res 362:175-179.
40. Morris JS, Frith CD, Perrett DI, Rowland D, Young AW, Calder AJ, Dolan RJ (1996): A differential neural response in the human amygdala to fearful and happy facial expressions. Nature 383:812-815.
41. Morris JS, Friston KJ, Buchel C, Frith CD, Young AW, Calder AJ, Dolan RJ (1998): A neuromodulatory role for the human amygdala in processing emotional facial expressions. Brain 121:47-57.
42. Morris JS, deBonis M, Dolan RJ (2002): Human amygdala responses to fearful eyes. Neuroimage 17:214-222.
43. Rauch SL, Shin LM (1997): Functional neuroimaging studies in posttraumatic stress disorder. Ann NY Acad Sci 821:83-98.
44. 2 in agoraphobics. Behav Res Ther 29:353-355.
45. Rehfeld JF (1985): Neuronal cholecystokinin: One or multiple transmitters? J Neurochem 44:1-10.
46. Rehfeld JF, Neilson FC (1995): Molecular form and regional distribution of cholecystokinin in the central and peripheral nervous system. In: Bradwejn J, Vasar E, editors. Cholecystokinin and Anxiety: From Neuron to Behaviour. Austin: Springer-Verlag-RG. pp 33-56.
47. Reiman EM, Raichle ME, Robins E, Mintun MA, Fusselman MJ, Fox PT, Price JL, Hackman KA (1989): Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry 46:493-500.
48. Sakai Y, Kumano H, Nishikawa M, Sakano Y, Kaiya H, Imabayashi E, Ohnishi T, Matsuda H, Yasuda A, Sato A, Diksic M, Kuboki T (2005): Cerebral glucose metabolism associated with a fear network in panic disorder. Neuroreport 16:927-931.
49. Schunck T, Erb G, Mathis A, Gilles C, Namer IJ, Hode Y, Demaziere A, Luthringer R, Macher JP (2006): Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage 31:1197-1208.
50. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997): Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332-340.
51. Spinhoven P, Onstein EJ, Sterk PJ, Haen-Versteijnen D (1993): Discordance between symptom and physiological criteria for the hyperventilation syndrome. J Psychosom Res 37:281-289.
52. Talaraich J, Tournoux P (1988): Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme.
53. van Megen HJ, Westenberg HG, den Boer JA, Haigh JR, Traub M (1994): Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder patients. Psychopharmacology (Berl) 114:449-455.
54. van Megen HJ, Westenberg HG, den Boer JA, Kahn RS (1996): Cholecystokinin in anxiety. Eur Neuropsychopharmacol 6:263-280.
55. van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A (1997): Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psycho-pharmacology (Berl) 129:357-364.
56. Whalen PJ, Rauch SL, Etcoff NL, McInerney SC, Lee MB, Jenike MA (1998): Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. J Neurosci 18:411-418.
57. Whalen PJ, Shin LM, McInerney SC, Fischer H, Wright CI, Rauch SL (2001): A functional MRI study of human amygdala responses to facial expressions of fear versus anger. Emotion 1:70-83.
58. Williams LM, Liddell BJ, Kemp AH, Bryant RA, Meares RA, Peduto AS, Gordon E (2006): Amygdala-prefrontal dissociation of subliminal and supraliminal fear. Hum Brain Mapp 27:652-661.
59. Windmann S (1998): Panic disorder from a monistic perspective: Integrating neurobiological and psychological approaches. J Anxiety Disord 12:485-507.
60. Zwanzger P, Eser D, Aicher S, Schule C, Baghai TC, Padberg F, Ella R, Moller HJ, Rupprecht R (2003): Effects of alprazolam on cholecystokinin- tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 28:979-984.